Sutro Biopharma (STRO) director receives 10,000 options vesting into 2027
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Sutro Biopharma director Joseph M. Lobacki received a grant of stock options for 10,000 shares of common stock. The options carry an exercise price of $26.09 per share and expire on June 5, 2036. Vesting is scheduled at 8.33% of the total award each month starting July 5, 2026, and the grant becomes fully vested and exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 5, 2027, subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Lobacki Joseph M
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 10,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 10,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 10,000 options
Exercise price: $26.09 per share
Option expiration: June 5, 2036
+1 more
4 metrics
Option grant size
10,000 options
Stock Option (right to buy) covering common stock
Exercise price
$26.09 per share
Conversion or exercise price for option grant
Option expiration
June 5, 2036
Expiration date of stock option award
Vesting schedule
8.33% of award monthly
Monthly vesting starting July 5, 2026 until fully vested by 2027
Key Terms
Stock Option (right to buy), exercise price, expiration date, vesting
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 26.0900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-05T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The option shall vest, subject to the reporting person's provision of service"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Sutro Biopharma (STRO) director Joseph Lobacki receive in this Form 4?
Joseph M. Lobacki received a grant of stock options for 10,000 shares of Sutro Biopharma common stock. These options represent a compensation-related award rather than an open-market purchase or sale of existing shares.
What is the exercise price of Joseph Lobacki’s Sutro Biopharma options?
The stock options granted to Joseph M. Lobacki have an exercise price of $26.09 per share. This is the fixed price at which he can buy Sutro Biopharma common shares once the options vest and are exercised.
When do Joseph Lobacki’s Sutro Biopharma options expire?
The stock options granted to Joseph M. Lobacki expire on June 5, 2036. After this expiration date, any unexercised options will no longer be exercisable, regardless of whether they had previously vested under the award terms.
How do Joseph Lobacki’s Sutro Biopharma options vest over time?
The options vest as to 8.33% of the total award each month, beginning July 5, 2026. The grant becomes fully vested and exercisable on the earlier of Sutro’s 2027 annual stockholders meeting or June 5, 2027, assuming continued service.